Roche gets US antitrust clearance for 89bio deal; intends to close Thursday
Roche said Thursday that it will close its $3.5 billion acquisition of liver drug developer 89bio. The announcement indicates that the companies have received clearance from the US antitrust authorities, which...To view the full article, register now.
Already a subscriber? Click here to view full article